Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top ...

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).

Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...

Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as ...

Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price ...

Takeda has announced the appointment of Julie Kim as the successor to Christophe Weber, effective from June 2026.

Takeda Pharmaceutical Company Limited ( NYSE: TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...

Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...